Prof. Dr. med. Dr. h.c. Ursula Ravens
Senior ProfessorResearch Interests:
- Electrical remodeling in cardiac disease (atrial fibrillation; heart failure)
- Cardiovascular pharmacology
- Functional role of cardiac ion channels; pharmacological modulation
- Regenerative potential of mesenchymal stem cells in the cardiovascular system
- Species differences in detrusor muscle function, pharmacological
Brief CV:
Ursula Ravens studied Medicine at the Albert-Ludwigs-University, Freiburg, and University of Vienna (1963-1969) and obtained her MD in 1969. After her internship in Berlin (Approbation 1970) she joined the Department of Pharmacology at the University of Kiel as a Scientific Research Fellow (1970-1985), where she specialized in Pharmacology (Facharzt 1977) and habilitated in Pharmacology in 1979. In 1985, Ursula became a Professor of Cardiovascular Pharmacology at the University of Essen, where she was elected as Dean for Students’ Affairs of the Medical Faculty (1986-1990). In 1997 Ursula took up the Professorship and Chair of Pharmacology and Toxicology at the Medical Faculty of Technical University of Dresden (1997-2014). Since 2014 she is a Senior Professor associated with the Department of Physiology, Medical Faculty at the Technical University of Dresden. She is Guest Professor at Danish Arrhythmia Research Centre, University of Copenhagen since 2009. Ursula was a Chairperson of several working groups and committees, was a member of the board of the German Pharmacological Society (DGP), and serves on diverse editoral boards. In 2015, Ursula was honoured with the Federal Cross of Merit. Since 2016, she is a Senior Professor at the IEKM in Freiburg.
Selected Publications:
- Rommel C [...] Ravens U, Hein L. The Transcription Factor ETV1 Induces Atrial Remodeling and Arrhythmia. Circ Res 2018/pii:CIRCRESAHA.118.313036
- Ravens U. Atrial-selective K+ channel blockers: potential antiarrhythmic drugs in atrial fibrillation? Can J Physiol Parmacol 2017/95:1313-1318
- Ravens U, Kohl P. Max Lab at heart. Prog Biophys Mol Biol 2017/130:124-125
- Katircioglu-Öztürk D, Güvenir HA, Ravens U, Baykal N. A window-based time series feature extraction method. Comput Biol Med 2017/89:466-486
- Ravens U, Odening KE. Atrial fibrillation: Therapeutic potential of atrial K+ channel blockers. Pharmacol Ther 2017/176:13-21
- Schmidt C, Wiedmann F [...] Ravens U [...] Thomas D. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Eur Heart J 2017/38:1764-1774
- Ford J, Milnes J, El Haou S, Wettwer E, Loose S, Matschke K, Tyl B, Round P, Ravens U. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm 2016/13:555-64
- Berk E, Christ T, Schwarz S, Ravens U, Knaut M, Kaumann AJ. In permanent atrial fibrillation phosphodiesterase3 reduces force responses to 5HT but neither PDE3 nor PDE4 influence abolished 5-HT-evoked arrhythmias. Br J Pharmacol. 2016/173:2478-89
- Christ T, Kovács PP, Wettwer E, Acsai K, Knaut M, Eschenhagen T, Iost N, Varró A, Ravens U. Block of Na+/Ca2+ exchanger by SEA0400 in human right atrial preparations from patients in sinus rhythm and in atrial fibrillation. Eur J Pharmacol. 2016/788:286-293
- Poulet C, Kuenzel S, Buettner E, Lindner D, Westermann D, Ravens U. Altered physiological functions and ion currents in atrial fibroblasts from patients with chronic atrial fibrillation. Physiol Report 2016/4:pii:e12681
- Skibsby L, Ravens U. Mechanism of proarrhythmic effects of potassium channel blockers. Card Electrophysiol Clin. 2016/8:395-410
- Edelmann JC, Jones L, Peyronnet R, Lu L, Kohl P, Ravens U. A Bioreactor to Apply Multi-Modal Physical Stimuli to Cultured Cells. Methods Mol Biol. 2016/1502:21-33
- Liberos A, Bueno-Orovio A, Rodrigo M, Ravens U, Hernández-Romero I, Fernández-Aviles F, Guillem MS, Rodriguez B, Climent AM. Balance between sodium and calcium currents underlying chronic atrial fibrillation termination: An in silico intersubject variability study. Heart Rhythm 2016/13:2358-2365
- Schmid E [...] Ravens U [...] Lorenz K. Cardiac RKIP causes a beneficial b-adrenoceptor-dependent positive inotropy. Nature Medicine 2015/21:1298-1306
- Schotten U, Hatem S, Ravens U [...] Camm J. The European Network for Translational Research in Atrial Fibrillation (EUTRAF): Objectives and Initial Results. Europace 2015/17:1457-1466
- Ravens U*, Katircioglu-ÖztürkD* [...] Güvenir HA. Application of the RIMARC algorithm to a large data set of action potentials and clinical parameters for risk prediction of atrial fibrillation. Med Biol Eng Comput 2015/53:263–273
- Turnow K [...] Ravens U, Wettwer E, Radicke S. Interaction of DPP10a with Kv4.3 channel complex results in a sustained current component of human transient outward current Ito. Bas Res Cardiol 2015/110:5
- Poulet C, Wettwer E [...] Ravens U. Late sodium current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation. PLOS ONE 2015/10:e0131432
- Sánchez C, Bueno-Orovio A [...] Ravens U, Pueyo E, Rodriguez B. Inter-subject variability in human atrial action potential in sinus rhythm versus chronic atrial fibrillation. PLoS One 2014/9:e105897
- Christ T, Rozmaritsa N [...] Ravens U, Kaumann A. Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation. PNAS USA 2014/111:11193-8
- Quinn TA, Kohl P, Ravens U. Cardiac mechano-electric coupling research: Fifty years of progress and scientific innovation. Prog Biophys Mol Biol 2014/115:71-75
- Skibsbye L, Poulet C [...] Ravens U [...] Jespersen T. Small-conductance calcium-activated potassium (SK) channels contribute to action potential repolarization in human atria. Cardiovasc Res 2014/103:156-67
- Loose S, Mueller J [...] Ravens U. Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation. Front Pharmacol 2014/4:26
- Rozmaritsa N, Christ T [...] Ravens U. Attenuated response of L-type calcium current to nitric oxide in atrial fibrillation. Cardiovasc Res 2014/101:533-42
- Kirchhof P [...] Ravens U [...] Camm AJ. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013/15:1540-56
- Lu L, Ravens U. The use of a novel cardiac bioreactor system in investigating fibroblast physiology and its perspectives. Organogenesis 2013/9:82-6
- Ravens U, Poulet C, Wettwer E, Knaut M. Atrial selectivity of antiarrhythmic drugs. J Physiol 2013/591:4087-97
- Voigt N [...] Ravens U, Dobrev D. Impaired Na⁺-dependent regulation of acetylcholine-activated inward-rectifier K⁺ current modulates action potential rate dependence in patients with chronic atrial fibrillation. J Mol Cell Cardiol 2013/61:142-52
- Molenaar P, Christ T [...] Ravens U, Levy FO, Kaumann AJ. PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol 2013/169:528-38
- Ford J, Milnes J [...] Ravens U. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol 2013/61:408-15
- Wettwer E, Christ T [...] Ravens U. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc Res 2013/98:145-54
- Lu L, Mende M [...] Ravens U. Design and validation of a bioreactor for simulating the cardiac niche: a system incorporating cyclic stretch, electrical stimulation, and constant perfusion. Tissue Eng Part A 2013/19:403-14
- Kirchhof P [...] Ravens U [...] Breithardt G. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012/380:238-46
- Protze S, Khattak S [...] Ravens U. A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. J Mol Cell Cardiol 2012/53:323-32
- Voigt N [...] Ravens U [...] Dobrev D. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed after depolarizations in patients with chronic atrial fibrillation. Circulation 2012/125:2059-70
- Bussek A [...] Ravens U, Wettwer E, Lohmann H. Cardiac tissue slices with prolonged survival for in vitro drug safety screening. J Pharmacol Toxicol Methods 2012/66:145-51
- Witt W [...] Ravens U [...] Waldow T. Sphingosine-1-phosphate induces contraction of valvular interstitial cells from porcine aortic valves. Cardiovasc Res 2012/93(3):490-7
- Dobrev D, Friedrich A [...] Ravens U. The G-protein gated potassium current I(K,Ach) is constitutively active in patients with chronic atrial fibrillation. Circulation 2005/112:3697-3706
- Heubach JF, Graf EM [...] Ravens U. Electrophysiological properties of human mesenchymal stem cells. J Physiol 2004/554:659-672
- Wettwer E, Hála O [...] Ravens U. Role of IKur in controlling action potential shape and contractility in the human atrium: Influence of chronic atrial fibrillation. Circulation 2004/110:2299-2306
- Wettwer E, Amos GJ, Posival H, Ravens U. Transient outward current (Ito) in human ventricular myocytes of subepi- and subendocardial origin. Circ Res 1994/75:473-482
- Wettwer E, Amos G [...] Ravens U. Transient outward current in human and rat ventricular myocytes. Cardiovasc Res 1993/27:1662-1669
- Isenberg G, Ravens U. The effects of the Anemonia sulcata toxin (ATX II) on membrane currents of isolated mammalian myocytes. J Physiol 1984/357:127-149
- Ravens U. Electromechanical studies of an Anemonia sulcata toxin in mammalian cardiac muscle. Naunyn-Schmiedeberg's. Arch Pharmacol 1976/296:73-78
- Kaufmann R, Theophile U. Automatiefördernde Dehnungseffekte an Purkinje-Fäden, Papillarmuskeln und Vorhoftrabekeln von Rhesus-Affen. Pflügers Arch 1967/297:174-189